Selected inputs.

<p>HPV: human papillomavirus,</p>a<p>Mean incidence reported for 2008–2010 for all HPV-related cancers except cervical cancer. Variation represents range in age-specific rates. Invasive cervical cancer incidence (used for calibration) is reported based on the pre-screening (1953–1969) mean of the minimum and maximum annual incidence from Norwegian Cancer Registry.</p>b<p>5-year relative survival is reported for calendar-period observation for 2006–2010; for cervical, the range represents stage-specific estimates for local (91%), regional (66%), and distant (19.9%).</p>c<p>Quality of life adjustment range from a health state utility weight of 0 (death) to 1 (perfect health). Weights for cervical cancer varied according to stage (local: 0.76 for five years; regional: 0.67 for five years; distant: 0.48 five years). Utility weights for other non-cervical HPV-related cancers are applied for five years. For genital warts, a mean quality of life loss of 6.6. days is assumed <a href="" target="_blank">[32]</a>, which is approximately a utility weight of 0.9277 over three months; for recurrent respiratory papillomatosis, health state utility weight of 0.68 over four years is assumed. Disease specific utility weights were multiplied to baseline age-specific utility weights <a href="" target="_blank">[29]</a> to estimate overall utility.</p>d<p>Cost per case is expressed in 2010 US dollars (1 USD = 6.05 Norwegian Kroner) and represent discounted (4% per year) costs for diagnosis and 5-year follow-up inclusive of direct (procedures, inpatient stays, general practitioner visits) and non-direct medical costs (transport) and patient time. The proportion of direct non-medical costs for all non-cervical conditions was estimated from cervical cancer (15%) and applied to baseline direct medical costs. Treatment of cervical cancer varies according to stage of detection (local: $25,800; regional: $51,600; distant: $59,600). See (<a href="" target="_blank"><b>File S1</b></a>) for estimation methods.</p>